Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Zevra Therapeutics (ZVRA) over the last 11 years, with Q3 2025 value amounting to -$544000.0.

  • Zevra Therapeutics' Net Income towards Common Stockholders rose 9836.27% to -$544000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $35.3 million, marking a year-over-year increase of 13939.71%. This contributed to the annual value of -$105.5 million for FY2024, which is 12912.77% down from last year.
  • Zevra Therapeutics' Net Income towards Common Stockholders amounted to -$544000.0 in Q3 2025, which was up 9836.27% from $74.7 million recorded in Q2 2025.
  • Zevra Therapeutics' Net Income towards Common Stockholders' 5-year high stood at $74.7 million during Q2 2025, with a 5-year trough of -$47.7 million in Q1 2021.
  • Over the past 5 years, Zevra Therapeutics' median Net Income towards Common Stockholders value was -$10.4 million (recorded in 2023), while the average stood at -$9.7 million.
  • In the last 5 years, Zevra Therapeutics' Net Income towards Common Stockholders tumbled by 134505.24% in 2021 and then surged by 47494.1% in 2025.
  • Over the past 5 years, Zevra Therapeutics' Net Income towards Common Stockholders (Quarter) stood at -$2.7 million in 2021, then crashed by 233.74% to -$9.0 million in 2022, then plummeted by 120.51% to -$19.9 million in 2023, then plummeted by 79.67% to -$35.7 million in 2024, then surged by 98.48% to -$544000.0 in 2025.
  • Its last three reported values are -$544000.0 in Q3 2025, $74.7 million for Q2 2025, and -$3.1 million during Q1 2025.